Medullary Thyroid Cancer Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment, By End-User, By Region & Competition, 2021-2031F

The global market for Medullary Thyroid Cancer (MTC) is projected to expand significantly, increasing from USD 1.48 billion in 2025 to USD 2.42 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 8.54%. This market focuses on the development and commercialization of specialized diagnostic tools and therapeutic interventions, primarily involving tyrosine kinase inhibitors and chemotherapy, to treat neuroendocrine tumors originating from parafollicular C cells. Key factors fueling this growth include the rising regulatory approvals for targeted therapies that specifically address RET genetic mutations and the increased adoption of genomic screening, which aids in early patient detection. According to the American Cancer Society, an estimated 44,020 new thyroid cancer cases are anticipated in the United States in 2025, highlighting the ongoing clinical necessity for effective management strategies across all disease subtypes. However, despite this positive growth outlook, the market faces significant hurdles, mainly due to the high costs of innovative orphan drugs, which create considerable reimbursement obstacles within cost-conscious healthcare systems. Such financial strain restricts broad patient access to advanced precision medicines and hinders manufacturers' efforts to expand revenue streams in emerging markets.

Market Driver

The primary catalyst for the Global Medullary Thyroid Cancer Market is the progress in targeted therapeutic development and regulatory approvals, which are fundamentally transforming treatment approaches from palliative care to precision oncology. The market is increasingly characterized by the commercialization of tyrosine kinase inhibitors specifically designed to inhibit RET proto-oncogene mutations, a common driver of medullary thyroid carcinoma. This shift towards targeted therapies is reinforced by the consistent revenue generated by approved orphan drugs; for instance, Exelixis reported Cometriq, its dedicated MTC therapy, generated $11.2 million in U.S. net product revenues for fiscal year 2024, as per their February 2025 financial results. These strong financial outcomes underscore the market's viability for specialized treatments and motivate manufacturers to ensure reliable supply chains for this specific patient demographic.A second significant driver is the escalating investment in oncology research and development, which supports the expensive clinical trials essential for bringing new therapeutic agents to market. Biopharmaceutical firms are dedicating considerable capital to broaden their product pipelines, motivated by the pressing clinical need to tackle the disease's higher mortality rate compared to other thyroid cancers. The American Cancer Society projected approximately 2,290 thyroid cancer deaths in the United States in 2025, highlighting the ongoing demand for more effective treatments. Consequently, industry frontrunners are increasing their expenditure on innovation; for example, Exelixis revised its full-year research and development expense guidance to up to $950 million in October 2024, signaling a substantial resource commitment to oncology development.

Market Challenge

The global Medullary Thyroid Cancer Market faces a significant obstacle in the form of the prohibitive costs linked to novel orphan drugs. This financial burden generates substantial reimbursement difficulties, especially within healthcare systems that operate under strict budget limitations or have insufficient public funding. Manufacturers of precision medicines, including tyrosine kinase inhibitors, typically price their products at a premium to recoup the considerable research and development investments made for treating this rare disease. As a result, payers often implement rigorous prior authorization protocols or deny coverage outright, directly restricting patient access to these advanced treatments and impeding the commercial adoption of new products.The market's challenges are compounded by the rarity of medullary thyroid cancer itself, which leads to these treatments being categorized as orphan drugs, inherently carrying higher per-unit costs. The American Thyroid Association noted that MTC constituted only about 1% to 2% of all thyroid cancer cases in the United States in 2025, emphasizing the market's niche character and making it challenging for pharmaceutical companies to achieve economies of scale. Ultimately, these economic pressures curtail revenue expansion in developing regions and hinder the broad implementation of effective management strategies.

Market Trends

The advancement of Peptide Receptor Radionuclide Therapy (PRRT) for metastatic cases is emerging as a crucial trend, providing a powerful therapeutic option for patients with progressive disease who no longer respond to conventional tyrosine kinase inhibitors. This innovative treatment leverages the high expression of somatostatin receptors on medullary thyroid carcinoma cells to deliver targeted cytotoxic radiation, thereby reducing systemic side effects. The industry's dedication to this approach is evident through significant capital investments aimed at accelerating clinical development pipelines. For example, ITM Isotope Technologies Munich SE announced in June 2024 that it secured an €188 million equity investment to advance its radiopharmaceutical candidates, signifying increasing commercial trust in targeted radionuclide interventions.Concurrently, the increasing adoption of highly selective RET kinase inhibitors is transforming the market by replacing less specific multikinase agents with precision medicines that offer enhanced safety profiles. In contrast to older therapies that inhibit multiple pathways, these newer generation drugs specifically target RET alterations, resulting in better patient adherence and prolonged clinical responses. This transition towards highly specific treatments is supported by the strong commercial performance of recently acquired assets in this area. Rigel Pharmaceuticals reported in November 2024 that its selective RET inhibitor, Gavreto, achieved $7.1 million in net product sales, highlighting the rapid market penetration and revenue potential of these specialized precision oncology therapies.

Key Market Players

• AstraZeneca PLC
• Sanofi AG
• Eli Lilly and Company
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co., Inc
• Bayer AG
• HUTCHMED Ltd.
• Bristol-Myers Squibb Co.

Report Scope

In this report, the Global Medullary Thyroid Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Medullary Thyroid Cancer Market, By Treatment

• Surgery
• Radiation Therapy
• Chemotherapy

Medullary Thyroid Cancer Market, By End-User

• Hospitals
• Radiation Therapy Center
• Cancer Research Institutes

Medullary Thyroid Cancer Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Medullary Thyroid Cancer Market.

Available Customizations:

Global Medullary Thyroid Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).